Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.


Autoria(s): Chudley L.; McCann K.J.; Coleman A.; Cazaly A.M.; Bidmon N.; Britten C.M.; van der Burg S.H.; Gouttefangeas C.; Jandus C.; Laske K.; Maurer D.; Romero P.; Schröder H.; Stynenbosch L.F.; Walter S.; Welters M.J.; Ottensmeier C.H.
Data(s)

2014

Resumo

Ex vivo ELISPOT and multimer staining are well-established tests for the assessment of antigen-specific T cells. Many laboratories are now using a period of in vitro stimulation (IVS) to enhance detection. Here, we report the findings of a multi-centre panel organised by the Association for Cancer Immunotherapy Immunoguiding Program to investigate the impact of IVS protocols on the detection of antigen-specific T cells of varying ex vivo frequency. Five centres performed ELISPOT and multimer staining on centrally prepared PBMCs from 3 donors, both ex vivo and following IVS. A harmonised IVS protocol was designed based on the best-performing protocol(s), which was then evaluated in a second phase on 2 donors by 6 centres. All centres were able to reliably detect antigen-specific T cells of high/intermediate frequency both ex vivo (Phase I) and post-IVS (Phase I and II). The highest frequencies of antigen-specific T cells ex vivo were mirrored in the frequencies following IVS and in the detection rates. However, antigen-specific T cells of a low/undetectable frequency ex vivo were not reproducibly detected post-IVS. Harmonisation of the IVS protocol reduced the inter-laboratory variation observed for ELISPOT and multimer analyses by approximately 20 %. We further demonstrate that results from ELISPOT and multimer staining correlated after (P < 0.0001 and R (2) = 0.5113), but not before IVS. In summary, IVS was shown to be a reproducible method that benefitted from method harmonisation.

Identificador

https://serval.unil.ch/?id=serval:BIB_DCEBADBFBEE5

isbn:1432-0851 (Electronic)

pmid:25134947

doi:10.1007/s00262-014-1593-0

isiid:000344324500008

http://my.unil.ch/serval/document/BIB_DCEBADBFBEE5.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_DCEBADBFBEE59

Idioma(s)

en

Direitos

info:eu-repo/semantics/openAccess

Fonte

Cancer Immunology, Immunotherapy : Cii, vol. 63, no. 11, pp. 1199-211

Tipo

info:eu-repo/semantics/article

article